CoChat

Vasopressin V1B Receptor Antagonists as Potential Antidepressants

Open access
Chaki, Shigeyuki · 2021 · International Journal of Neuropsychopharmacology

The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.

Abstract

Accumulating evidence shows that certain populations of depressed patients have impaired hypothalamus-pituitary-adrenal (HPA) axis function. Arginine-vasopressin (AVP) is one of the primary factors in HPA axis regulation under stress situations, and AVP and its receptor subtype (V1B receptor) play a pivotal role in HPA axis abnormalities observed in depression. Based on this hypothesis, several non-peptide V1B receptor antagonists have been synthesized, and the efficacies of some V1B receptor antagonists have been investigated in both animals and humans. V1B receptor antagonists exert antidepressant-like effects in several animal models at doses that attenuate the hyperactivity of the HPA axis, and some of their detailed mechanisms have been delineated. These results obtained in animal models were, at least partly, reproduced in clinical trials. At least 2 V1B receptor antagonists (TS-121 and ABT-436) showed tendencies to reduce the depression scores of patients with major depressive disorder at doses that attenuate HPA axis hyperactivity or block the pituitary V1B receptor. Importantly, TS-121 showed a clearer efficacy for patients with higher basal cortisol levels than for those with lower basal cortisol levels, which was consistent with the hypothesis that V1B receptor antagonists may be more effective for patients with HPA axis hyperactivity. Therefore, V1B receptor antagonists are promising approaches for the treatment of depression involving HPA axis impairment such as depression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ijnp/pyab013

Cites

95 of 95 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Regulation of hypothalamus-pituitary-adrenal (HPA) axis by arginine-vasopressin (AVP) (A) and extrahypothalamic AVP system (B). (A) Both AVP and corticotropin-releasing factor (CRF) produced in the paraventricular nucleus (PVN) of the hypothalamus act on V1B and CRF1 receptors in the pituitary, respectively, to stimulate adrenocorticotropic hormone (ACTH) release from the anterior pituitary. In response to ACTH, the cortex of the adrenal glands produces cortisol (corticosterone in rodents), which penetrates the blood–brain barrier and exerts its actions in the brain through the high-affinity mineralocorticoid receptors and the low-affinity glucocorticoid receptors. Cortisol provides negative feedback at the limbic, hypothalamic, and pituitary level. In contrast, the amygdala enhances CRF production in the PVN. The AVP and V1B receptor systems are rather resistant to feedback mechanisms via cortisol. Under chronic stress, the proportion of AVP-containing neurons among the CRF neurons in the PVN increases. In addition, the pituitary V1B receptor is upregulated, while the pituitary CRF1 receptor is downregulated by chronic stress. (B) The V1B receptor is expressed in the brain, including the lateral septum and amygdaloid nuclei, and V1B receptors in these nuclei are postulated to play some roles in the regulation of emotion. BLN, basolateral nucleus; CeN, central nucleus; MeN, medial nucleus.
Figure 1. Regulation of hypothalamus-pituitary-adrenal (HPA) axis by arginine-vasopressin (AVP) (A) and extrahypothalamic AVP system (B). (A) Both AVP and corticotropin-releasing factor (CRF) produced in the paraventricular nucleus (PVN) of the hypothalamus act on V1B and CRF1 receptors in the pituitary, respectively, to stimulate adrenocorticotropic hormone (ACTH) release from the anterior pituitary. In response to ACTH, the cortex of the adrenal glands produces cortisol (corticosterone in rodents), which penetrates the blood–brain barrier and exerts its actions in the brain through the high-affinity mineralocorticoid receptors and the low-affinity glucocorticoid receptors. Cortisol provides negative feedback at the limbic, hypothalamic, and pituitary level. In contrast, the amygdala enhances CRF production in the PVN. The AVP and V1B receptor systems are rather resistant to feedback mechanisms via cortisol. Under chronic stress, the proportion of AVP-containing neurons among the CRF neurons in the PVN increases. In addition, the pituitary V1B receptor is upregulated, while the pituitary CRF1 receptor is downregulated by chronic stress. (B) The V1B receptor is expressed in the brain, including the lateral septum and amygdaloid nuclei, and V1B receptors in these nuclei are postulated to play some roles in the regulation of emotion. BLN, basolateral nucleus; CeN, central nucleus; MeN, medial nucleus.CC BY-NC · PubMed Central
Figure 2. Chemical structures and profiles of representative V1B receptor antagonists.
Figure 2. Chemical structures and profiles of representative V1B receptor antagonists.CC BY-NC · PubMed Central
Figure 3. Conceptualized scheme for patient segmentation for V1B receptor antagonists treatment. Among patients with major depressive disorder (MDD), there are certain populations with impaired hypothalamus-pituitary-adrenal (HPA) axis who might show higher cortisol levels in blood, urine, or saliva. Moreover, even among MDD patients with impaired HPA activity, there are certain populations of patients with V1B receptor hyperactivation. It is important to appropriately stratify patients who could respond better to V1B receptor antagonists.
Figure 3. Conceptualized scheme for patient segmentation for V1B receptor antagonists treatment. Among patients with major depressive disorder (MDD), there are certain populations with impaired hypothalamus-pituitary-adrenal (HPA) axis who might show higher cortisol levels in blood, urine, or saliva. Moreover, even among MDD patients with impaired HPA activity, there are certain populations of patients with V1B receptor hyperactivation. It is important to appropriately stratify patients who could respond better to V1B receptor antagonists.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 95 references

Cited by

See all 34

Metadata

Authors
Chaki, S.
Affiliations
Taisho Pharmaceutical (Japan) (JP)
Corresponding author
Chaki, Shigeyuki
Venue
International Journal of Neuropsychopharmacology
Published
2021-03-18
Volume
24
Issue
6
Pages
450-463
ISSN
  • 1461-1457 (ISSN-L)
  • 1469-5111
OpenAlex
W3138981265
Cited by
34
References
95
Citations by year
2026: 4 · 2025: 9 · 2024: 9 · 2023: 6 · 2022: 3 · 2021: 3
FWCI
0.63
Type
journal article
Language
en
Open access
Locations
  • The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
Keywords
depression, hypothalamic-pituitary-adrenal axis, vasopressin, major depressive disorder, basal cortisol, antidepressant efficacy, stress response
MeSH terms
Animals, Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Humans, Hypothalamo-Hypophyseal System, Receptors, Vasopressin, Antidiuretic Hormone Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vasopressin V1B Receptor Antagonists as Potential Antidepressants. https://app.cochat.ai/papers/10.1093/ijnp/pyab013
The paper
Chaki, S. (2021). Vasopressin V1B Receptor Antagonists as Potential Antidepressants. International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyab013

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.